 |
|
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
Jung-Wee Park
J Bone Metab. 2021;28(4):339-341. Published online 2021 Nov 30 DOI: https://doi.org/10.11005/jbm.2021.28.4.339
|
|
Citations to this article as recorded by
 Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
Soher Nagi Jayash, Dounia Hamoudi, Louise A. Stephen, Anteneh Argaw, Carmen Huesa, Shuko Joseph, Sze Choong Wong, Jérôme Frenette, Colin Farquharson
Calcified Tissue International.2023; 113(4): 449. CrossRef
|